SARC Biannual Meeting
November 1, 2007
| Thursday, November 1, 2007 |
||
| 8:00 AM–8:15 AM |
Welcome/SARC Update | Laurence Baker |
| 8:15 AM–9:00 AM |
Chawla/Rosenfeld Developmental Therapeutics Symposium | Lee Helman |
| 9:00 AM–10:15 AM |
Review of Ongoing SARC Trials |
|
| SARC 003 Gemcitabine/Docetaxel in Bone Sarcoma | Beth Fox | |
| SARC 004 Neoadjuvant Imatinib in DFSP | Scott Schuetze | |
| SARC 005 Adjuvant Therapy High Risk Uterine Leiomyosarcoma | Martee Hensley | |
| SARC 006 MPNST: Sporatic versus NF1 associated | Brigitte Widemann | |
| SARC 007 Perifosine in chemoinsensitive sarcoma | (TBD) | |
| SARC 009 Dasatinib in metastatic sarcoma | Scott Schuetze | |
| Review of Pending Trials | ||
| SARC 010 Dasatinib in GIST | Jon Trent | |
| SARC 011 IGF-1R in selected sarcomas | Alberto Pappo | |
| SARC 012 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung | (TBD) | |
|
|
Prioritizing SARC Studies | Laurence Baker |
| 10:15 AM–10:30 AM |
Break |
|
| 10:30 AM–12:00 PM |
Closed Session (Limited to attendees who have signed CDA with SARC) |
|